Division and Department

Department of Psychiatry

A Greeting from the Professor

Psychiatry covers all aspects of disorders of ABC: affect, behavior and cognition. As a university hospital, with a clinic for general psychiatry, we run a sleep disorder clinic specializing in insomnia, excessive daytime sleepiness and sleep-wake rhythm disorder.

The policy of our course for residents in psychiatry is to develop practical skills to be a general psychiatrist, and our course provides the opportunity to obtain a physician's license recognized by the Ministry of Health, Labor and Welfare, and to become an Accredited Psychiatric Specialist recognized by the Japanese Society of Psychiatry and Neurology. For this purpose, we allow students to train both in a mental hospital and in the psychiatric ward of a general hospital as well as at the university hospital.

Residents are highly encouraged to enter a graduate school of medicine to obtain a doctoral degree. Studying abroad is also encouraged. So far, our colleagues have worked at Ottawa University (Canada), Edinburgh University (UK), Stanford University (USA), Emory University (USA), and Vita-Salute San Raffaele University (Italy).

I cordially welcome all young colleagues who have interest in any aspects of the human mind to our department. Let's sail together on the mystic ocean of the mind!

Staff

Professor:
Kazuo MISHIMA, M.D. (Psychiatry)

Lecturer:
Masahiro TAKESHIMA, M.D. (Psychiatry)

Research Areas

  1. Clinical research on predictors of recurrence of psychiatric disorders
  2. Development of precise diagnosis and treatment of sleep-wake disorders
  3. Research on guidelines for the proper use of psychotropic drugs

Contact Information

Lecture Masahiro TAKESHIMA
Phone: +81-18-884-6122
Fax: +81-18-884-6445
E-mail: m.takeshima@med.akita-u.ac.jp

Most Recent Achievements

  1. Yamada H, Motoyama M, Hasegawa N, et al. A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project. BJPsych Open 2022; 8(3): e83.
  2. Umakoshi A, Takeshima M, Itoh Y, et al. Relationship among psychotic features, benzodiazepine receptor agonists, and rehospitalization in patients with electroconvulsive therapy-responsive major depressive disorder: A retrospective 2-year observational study. Neuropsychopharmacol Rep 2022.
  3. Takeshima M, Enomoto M, Ogasawara M, et al. Changes in psychotropic polypharmacy and high-potency prescription following policy change: Findings from a large scale Japanese claims database. Psychiatry and clinical neurosciences 2022; 76(9): 475-7.
  4. Sugano Y, Miyachi T, Ando T, et al. Diabetes and anxiety were associated with insomnia among Japanese male truck drivers. Sleep Med 2022; 90: 102-8.
  5. Ogasawara M, Takeshima M, Esaki Y, et al. Comparison of the efficacy and safety of quetiapine and lithium for bipolar depression: A systematic review and meta-analysis of randomized controlled trials. Neuropsychopharmacol Rep 2022.
  6. Ogasawara K, Numata S, Hasegawa N, et al. Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. Neuropsychopharmacol Rep 2022; 42(2): 221-5.
  7. Ochi S, Tagata H, Hasegawa N, et al. Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: A real-world nationwide study. Int J Neuropsychopharmacol 2022.
  8. Nomura K, Yamazaki T, Maeda E, et al. Longitudinal survey of depressive symptoms among university students during the COVID-19 pandemic in Japan. Front Psychol 2022; 13: 863300.
  9. Narita Z, Yamanouchi Y, Mishima K, et al. Training types associated with knowledge and experience in public health workers. Arch Public Health 2022; 80(1): 44.
  10. Muraoka H, Kodaka F, Hasegawa N, et al. Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site study. Asian J Psychiatr 2022; 74: 103174.
  11. Miyagawa T, Tanaka S, Shimada M, et al. A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia. NPJ Genom Med 2022; 7(1): 29.
  12. Itoh Y, Takeshima M, Kaneita Y, et al. Associations Between the 2011 Great East Japan Earthquake and Tsunami and the Sleep and Mental Health of Japanese People: A 3-Wave Repeated Survey. Nature and science of sleep 2022; 14: 61-73.
  13. Ikeda S, Azuma M, Fujimoto K, et al. Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents. Psychol Med 2022: 1-13.
  14. Ichihashi K, Kyou Y, Hasegawa N, et al. The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project. Asian J Psychiatr 2022; 69: 103007.
  15. Hori H, Yasui-Furukori N, Hasegawa N, et al. Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics. Front Psychiatry 2022; 13: 823826.
  16. Hayashi M, Mishima K, Fukumizu M, et al. Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial. J Autism Dev Disord 2022; 52(6): 2784-93.
  17. Furihata R, Otsuki R, Hasegawa N, et al. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study. Sleep Med 2022; 89: 23-30.
  18. Ayabe N, Nakajima S, Okajima I, et al. Development and validation of the Japanese version of the Hyperarousal Scale. BMC psychiatry 2022; 22(1): 617.
  19. Aoki Y, Takaesu Y, Suzuki M, et al. Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics. Neuropsychopharmacol Rep 2022; 42(1): 10-20.
  20. Akashiba T, Inoue Y, Uchimura N, et al. Sleep Apnea Syndrome (SAS) Clinical Practice Guidelines 2020. Respir Investig 2022; 60(1): 3-32.
  21. Yoshizawa K, Takeshima M, Ishino S, et al. Severity of Depressive Symptoms is Associated with Venous Thromboembolism in Hospitalized Patients with a Major Depressive Episode. Neuropsychiatric disease and treatment 2021; 17: 2955-63.
  22. Yamato K, Inada K, Enomoto M, Marumoto T, Takeshima M, Mishima K. Patterns of hypnotic prescribing for residual insomnia and recurrence of major depressive disorder: a retrospective cohort study using a Japanese health insurance claims database. BMC psychiatry 2021; 21(1): 40.
  23. Yamamoto M, Inada K, Enomoto M, et al. Current state of hypnotic use disorders: Results of a survey using the Japanese version of Benzodiazepine Dependence Self-Report Questionnaire. Neuropsychopharmacol Rep 2021; 41(1): 14-25.
  24. Takeshima M, Otsubo T, Funada D, et al. Does cognitive behavioral therapy for anxiety disorders assist the discontinuation of benzodiazepines among patients with anxiety disorders? A systematic review and meta-analysis. Psychiatry and clinical neurosciences 2021; 75(4): 119-27.
  25. Takeshima M, Ohta H, Hosoya T, et al. Association between sleep habits/disorders and emotional/behavioral problems among Japanese children. Scientific reports 2021; 11(1): 11438.
  26. Takeshima M, Ishikawa H, Ogasawara M, et al. The Usefulness of the Combination of D-Dimer and Soluble Fibrin Monomer Complex for Diagnosis of Venous Thromboembolism in Psychiatric Practice: A Prospective Study. Vasc Health Risk Manag 2021; 17: 239-46.
  27. Stickley A, Shirama A, Kitamura S, et al. Attention-deficit/hyperactivity disorder symptoms and sleep problems in preschool children: the role of autistic traits. Sleep Med 2021; 83: 214-21.
  28. Numata S, Nakataki M, Hasegawa N, et al. Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep 2021; 41(2): 199-206.
  29. Nomura K, Minamizono S, Maeda E, et al. Cross-sectional survey of depressive symptoms and suicide-related ideation at a Japanese national university during the COVID-19 stay-home order. Environ Health Prev Med 2021; 26(1): 30.
  30. Narisawa H, Inoue Y, Kobayashi M, et al. Development and validation of the Benzodiazepine Hypnotics Withdrawal Symptom Scale (BHWSS) based on item response theory. Psychiatry Res 2021; 300: 113900.
  31. Nakagawa M, Ohta H, Shimabukuro R, et al. Daytime nap and nighttime breastfeeding are associated with toddlers' nighttime sleep. Scientific reports 2021; 11(1): 3028.
  32. Motomura Y, Kitamura S, Nakazaki K, et al. The Role of the Thalamus in the Neurological Mechanism of Subjective Sleepiness: An fMRI Study. Nature and science of sleep 2021; 13: 899-921.
  33. Motomura Y, Katsunuma R, Ayabe N, et al. Decreased activity in the reward network of chronic insomnia patients. Scientific reports 2021; 11(1): 3600.
  34. Miyachi T, Nomura K, Minamizono S, et al. Factors Associated with Insomnia Among Truck Drivers in Japan. Nature and science of sleep 2021; 13: 613-23.
  35. Masunaga Y, Kagami M, Kato F, et al. Parthenogenetic mosaicism: generation via second polar body retention and unmasking of a likely causative PER2 variant for hypersomnia. Clin Epigenetics 2021; 13(1): 73.
  36. Kishi T, Sakuma K, Okuya M, et al. Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. Bipolar Disord 2021; 23(8): 789-800.
  37. Kishi T, Matsuda Y, Sakuma K, Okuya M, Mishima K, Iwata N. Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis. Psychol Med 2021; 51(15): 2721-9.
  38. Kishi T, Ikuta T, Matsuda Y, et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry 2021; 26(8): 4146-57.
  39. Kato M, Hori H, Inoue T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry 2021; 26(1): 118-33.
  40. Ishizuya A, Enomoto M, Tachimori H, et al. Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder. Scientific reports 2021; 11(1): 1707.
  41. Ishikawa H, Takeshima M, Ishikawa H, Ayabe N, Ohta H, Mishima K. Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review. Neuropsychopharmacol Rep 2021; 41(3): 434-9.
  42. Inada K, Enomoto M, Yamato K, Mishima K. Prescribing Pattern of Hypnotic Medications in Patients Initiating Treatment at Japanese Hospitals: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Claims Database. Drugs Real World Outcomes 2021; 8(3): 277-88.
  43. Inada K, Enomoto M, Yamato K, Marumoto T, Takeshima M, Mishima K. Effect of residual insomnia and use of hypnotics on relapse of depression: a retrospective cohort study using a health insurance claims database. J Affect Disord 2021; 281: 539-46.
  44. Imanishi A, Omori Y, Ishido H, et al. Aripiprazole as a new treatment for the prolonged nocturnal sleep of patient with idiopathic hypersomnia. Psychiatry and clinical neurosciences 2021; 75(10): 320-2.
  45. Hashimoto N, Yasui-Furukori N, Hasegawa N, et al. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. Asian J Psychiatr 2021; 63: 102744.
  46. Ando A, Ohta H, Yoshimura Y, et al. Sleep maturation influences cognitive development of preterm toddlers. Scientific reports 2021; 11(1): 15921.
  47. Yuge K, Nagamitsu S, Ishikawa Y, et al. Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders. BMC psychiatry 2020; 20(1): 445.
  48. Takeshima M, Utsumi T, Aoki Y, et al. Efficacy and safety of bright light therapy for manic and depressive symptoms in patients with bipolar disorder: A systematic review and meta-analysis. Psychiatry and clinical neurosciences 2020; 74(4): 247-56.
  49. Takeshima M, Utsumi T, Aoki Y, et al. Response to 'Efficacy and safety of bright light therapy for bipolar depression'. Psychiatry and clinical neurosciences 2020; 74(7): 410-1.
  50. Takeshima M, Shimizu T, Ishikawa H, Kanbayashi T. Ramelteon for Delayed Sleep-wake Phase Disorder: A Case Report. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology 2020; 18(1): 167-9.
  51. Takeshima M, Ishikawa H, Umeta Y, et al. Prevalence of Asymptomatic Venous Thromboembolism in Depressive Inpatients. Neuropsychiatric disease and treatment 2020; 16: 579-87.
  52. Takahashi Y, Shindo S, Kanbayashi T, Takeshima M, Imanishi A, Mishima K. Examination of the influence of cedar fragrance on cognitive function and behavioral and psychological symptoms of dementia in Alzheimer type dementia. Neuropsychopharmacol Rep 2020; 40(1): 10-5.
  53. Miidera H, Enomoto M, Kitamura S, Tachimori H, Mishima K. Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes: A Large, Population-Based Cohort Study in Japan. Diabetes Care 2020; 43(4): 885-93.
  54. Kishi T, Sakuma K, Okuya M, et al. Recurrence of Mania or Depression Among Adult Bipolar Patients Who Continued Using Lithium: A Single-group Summary Meta-analysis of Randomized Trials. Journal of clinical psychopharmacology 2020; 40(5): 468-74.
  55. Enomoto M, Kitamura S, Tachimori H, Takeshima M, Mishima K. Long-term use of hypnotics: Analysis of trends and risk factors. Gen Hosp Psychiatry 2020; 62: 49-55.
  56. Abe T, Mishima K, Kitamura S, et al. Tracking intermediate performance of vigilant attention using multiple eye metrics. Sleep 2020; 43(3).

back